Pharvaris N.V. (NASDAQ:PHVS) Receives $49.18 Consensus Target Price from Brokerages

Pharvaris N.V. (NASDAQ:PHVS) has been assigned a consensus rating of “Moderate Buy” from the thirteen brokerages that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and ten have given a buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $49.1818.

PHVS has been the subject of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price target on shares of Pharvaris in a research note on Tuesday, March 3rd. Wedbush lifted their price target on shares of Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a research note on Tuesday, April 7th. Wall Street Zen raised shares of Pharvaris from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Citigroup reissued a “buy” rating on shares of Pharvaris in a research report on Wednesday, April 15th. Finally, Wolfe Research initiated coverage on shares of Pharvaris in a research report on Thursday, April 9th. They set an “outperform” rating and a $42.00 target price for the company.

Insider Activity at Pharvaris

In other news, CEO Berndt Modig sold 2,292 shares of the business’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $29.22, for a total transaction of $66,972.24. Following the completion of the sale, the chief executive officer directly owned 137,500 shares of the company’s stock, valued at $4,017,750. The trade was a 1.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Viviane Monges sold 9,667 shares of the business’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $30.29, for a total transaction of $292,813.43. Following the sale, the director directly owned 5,500 shares of the company’s stock, valued at approximately $166,595. The trade was a 63.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 209,948 shares of company stock valued at $6,268,141 over the last quarter.

Institutional Investors Weigh In On Pharvaris

Several hedge funds and other institutional investors have recently made changes to their positions in PHVS. Geode Capital Management LLC increased its position in shares of Pharvaris by 41.1% during the second quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock worth $952,000 after acquiring an additional 15,769 shares in the last quarter. JPMorgan Chase & Co. grew its position in Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after purchasing an additional 783 shares in the last quarter. Legal & General Group Plc grew its position in Pharvaris by 17.2% in the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after purchasing an additional 1,695 shares in the last quarter. Amundi grew its position in Pharvaris by 2,741,600.0% in the 2nd quarter. Amundi now owns 27,417 shares of the company’s stock worth $489,000 after purchasing an additional 27,416 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in Pharvaris by 19.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company’s stock worth $860,000 after purchasing an additional 7,879 shares in the last quarter.

Pharvaris Trading Down 0.4%

PHVS opened at $28.98 on Wednesday. Pharvaris has a 1-year low of $15.91 and a 1-year high of $33.33. The company has a market cap of $1.90 billion, a P/E ratio of -9.11 and a beta of -2.35. The company has a fifty day moving average price of $28.86 and a two-hundred day moving average price of $27.16.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.12. On average, research analysts forecast that Pharvaris will post -3.25 EPS for the current fiscal year.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.